GE Healthcare gets FDA approval for Invenia ABUS

4 June 2014 (Last Updated June 4th, 2014 18:30)

GE Healthcare has received approval from the US Food and Drug Administration for its new breast imaging technology, the Invenia Automated Breast Ultrasound System (ABUS) for improved diagnosis of cancer in women with dense tissue in the area.

GE Healthcare has received approval from the US Food and Drug Administration for its new breast imaging technology, the Invenia Automated Breast Ultrasound System (ABUS) for improved diagnosis of cancer in women with dense tissue in the area.

Invenia ABUS is expected to help clinicians find 35.7% more cancers in women with dense breasts than mammograms alone.

GE Healthcare has unveiled the first Invenia ABUS installations with Fairfax Radiological Consultants just outside of Washington and Phelps Memorial Hospital Center in Sleepy Hollow.

Fairfax Radiological Consultants breast imaging specialist Elise Berman said a growing body of research suggests the importance of screening ultrasound for the 40% of women with dense breast tissue.

"Supplementing the mammogram with automated breast ultrasound screenings should help us find tumours that cannot be seen on the mammogram and at an earlier stage than would have otherwise been found."

"Mammography is still considered the gold standard for breast cancer screening but is less sensitive in women who have dense breast tissue," Berman said.

"Supplementing the mammogram with automated breast ultrasound screenings should help us find tumours that cannot be seen on the mammogram and at an earlier stage than would have otherwise been found."

The Invenia ABUS improves the patient experience by using 3D ultrasound technology to comfortably and quickly image women with dense breast tissue in about 15 minutes with new features that conform to a woman's body and provide more enhanced images.

Phelps Memorial Hospital Center senior administrative director of Ancillary Services Michael Glennon said: "This highly sophisticated ABUS is more efficient than the traditional ultrasound exam and will significantly enhance our diagnostic capabilities and potentially improve outcomes for our patients."

The company has designed the Invenia ABUS with the patented Reverse Curve transducer to conform to a woman's anatomy, for better comfort and image performance.

In addition, the system uses compression assist, which applies light levels of compression automatically to the breast for increased ease and image reproducibility.

Following the initial Fairfax and Sleepy Hollow launches, the company has plans to introduce Invenia ABUS later this year to health providers across the US.

GE ultrasound business president and CEO Anders Wold said: "As part of our ongoing commitment to improving women's health, GE Healthcare is focused on providing timely and meaningful technological innovations spanning the care continuum, including those for the screening of patients with dense breasts."

The more dense breast tissue a woman has, the greater her risk of developing breast cancer.